Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2002

Methylin(Methylphenidate Hcl)Shionogi & Co., Ltd. logo4507.T

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Shionogi & Co., Ltd.

$2,773

Medicare cost, 2024

Medicare drug plans spent $2,773 on Methylin (methylphenidate hcl) in 2024, for 31 prescriptions and refills. Spending fell 30% from 2023 to 2024. It is made by Shionogi & Co., Ltd. (4507.T).

Medicare cost, 2024

$2,773

-29.8% from 2023

Prescriptions

31

$89.46 per claim

Patients

-

10 prescribers

Total spending, 2024

$2,773

- per patient

Questions and answers

How much does Medicare spend on Methylin?

Medicare prescription drug plans paid $2,773 for Methylin in 2024, for 31 prescriptions and refills to - patients (down 29.8% from 2023). The average cost per claim was $89.46.

Who makes Methylin?

Methylin is made by Shionogi & Co., Ltd. (4507.T), listed in the Medicare spending data as Shionogi Pharma.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Methylin was $2,773 in 2024, after a high of $3,950 in 2023.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022817-$2,538
2023124412$3,950
20241031-$2,773

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Shionogi Pharma4507.T logo4507.T31$2,773

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
2
RxNorm concept IDs
1091133, 1091135, 1091341, 1091343
Application numbers
NDA021419

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube